Legend Biotech Corporation (LEGN)
| Market Cap | 5.20B -17.3% |
| Revenue (ttm) | 1.03B +64.0% |
| Net Income | -296.80M |
| EPS | -1.62 |
| Shares Out | 184.94M |
| PE Ratio | n/a |
| Forward PE | 104.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,600,481 |
| Open | 28.39 |
| Previous Close | 28.57 |
| Day's Range | 27.69 - 29.50 |
| 52-Week Range | 16.24 - 45.30 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 61.33 (+118.1%) |
| Earnings Date | May 12, 2026 |
About LEGN
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym... [Read more]
Financial Performance
In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for LEGN stock is "Strong Buy." The 12-month stock price target is $61.33, which is an increase of 118.10% from the latest price.
News
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguish...
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET ...
Legend Biotech price target lowered to $49 from $50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Legend Biotech (LEGN) to $49 from $50 and keeps an Overweight rating on the shares. The firm, which updated estimates following the
Legend Biotech price target lowered to $62 from $66 at RBC Capital
RBC Capital lowered the firm’s price target on Legend Biotech (LEGN) to $62 from $66 and keeps an Outperform rating on the shares after its Q4 results. The firm sees
Legend Biotech Earnings Call Transcript: Q4 2025
Q4 2025 saw 66% year-over-year CARVYKTI sales growth, driving profitability for the franchise and strong revenue gains. Manufacturing capacity and global reach expanded, with 65% of patients now treated in earlier lines. Company-wide profitability is expected in 2026.
Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year
Reports Q4 revenue $306.3M, consensus $310.21M. “CARVYKTI continued to build on its leadership in multiple myeloma CAR-T in 2025, as we reached more than 10,000 patients treated and achieved franchise
Legend Biotech sees cash runway beyond 2026
As of December 31, 2025, Legend Biotech (LEGN) had approximately $949 million of cash and cash equivalents and time deposits.
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter ...
Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank
Deutsche Bank attributes the 46% selloff in Legend Biotech (LEGN) shares over the past 12 months to market share concerns are “overblown and dislocated from fundamentals.” The firm is aware
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET o...
Legend Biotech rises 16.6%
Legend Biotech (LEGN) is up 16.6%, or $3.01 to $21.13.
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Qize Ding downgraded Legend Biotech (LEGN) to Neutral from Buy with a price target of $24, down from $83. The firm believes Legend Biotech’s only
Legend Biotech price target lowered to $80 from $90 at Barclays
Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $90 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for
Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Legend Biotech (LEGN) to $50 from $60 and keeps a Buy rating on the shares. The firm says Carvytki generated $555M in
Legend Biotech downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Legend Biotech (LEGN) to Hold from Buy with a price target of $21, down from $62. The company’s Q4 miss for Carvykti at $555M vs consensus $582M
Legend Biotech falls -12.7%
Legend Biotech (LEGN) is down -12.7%, or -$2.97 to $20.45.
Legend Biotech falls -10.5%
Legend Biotech (LEGN) is down -10.5%, or -$2.46 to $20.96.
FDA draft guidance favorable for Legend Biotech, says RBC Capital
The FDA issued draft guidance supporting the use of minimal residual disease negativity and complete response rate as accelerated approval endpoints in multiple myeloma, signaling an effort to speed d...
Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference
CARVYKTI achieved $1.7B in sales, treated over 10,000 patients, and is expanding globally with strong clinical data and manufacturing scale. Early-line use is rising, pipeline innovation is accelerating, and profitability is expected in 2026.
Legend Biotech sees cash runway beyond 2026
Legend Biotech (LEGN) provided an update on the Company’s recent commercial and clinical progress and outlined its strategic priorities for 2026. These updates will be discussed as part of the
Legend Biotech initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Legend Biotech (LEGN) with an Outperform rating and $75 price target The firm notes the company commercializes Carvykti, a multiple-myeloma CAR-T therapy whose sales ...
Legend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Legend Biotech (LEGN) to $74 from $75 and keeps an Overweight rating on the shares. Despite heightened discussion around competition at ASH,
Legend Biotech management to meet with Cantor Fitzgerald
Group Luncheon Meeting to be held in New York on December 16 hosted by Cantor Fitzgerald.
Legend Biotech price target lowered to $50 from $83 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Legend Biotech (LEGN) to $50 from $83 and keeps an Overweight rating on the shares. The firm expects many of the policy
Cancer Study Buoys These Small Biotechs
Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.